Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 4, 2024
Daily News
September 4, 2024
- Kidswell Is Open to M&As Amid Challenging Financing Environment: CEO
September 4, 2024
- Japan Healthcare Spend Hit Record High of 47 Trillion Yen in FY2023
September 4, 2024
- Japan’s HIV and AIDS Cases Up for First Time in 7 Years
September 4, 2024
- Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
September 4, 2024
- PDRadiopharma’s PET Imaging Agent Amyvid Widens Label Too
September 4, 2024
- Asahi Kasei Closes Tender Offer for Calliditas, Enriches Renal Franchise
September 4, 2024
- Stella Pharma, NCC, Sumitomo Heavy Industries Tie Up in BNCT Basket Trial
September 4, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…